Unlock stock picks and a broker-level newsfeed that powers Wall Street.
editorial-team@simplywallst.com (Simply Wall St)
4 min read
As global markets grapple with economic uncertainty and inflation concerns, the Asian markets have shown resilience, with investors keenly eyeing value stocks that may offer stability amid volatility. In this context, identifying undervalued stocks in Asia could provide opportunities for those looking to navigate these challenging times by focusing on companies with strong fundamentals and potential for growth.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
DIP (TSE:2379) |
¥2299.00 |
¥4575.97 |
49.8% |
|
Zhejiang Cfmoto PowerLtd (SHSE:603129) |
CN¥183.48 |
CN¥359.71 |
49% |
|
Consun Pharmaceutical Group (SEHK:1681) |
HK$8.95 |
HK$17.64 |
49.3% |
|
Chison Medical Technologies (SHSE:688358) |
CN¥31.17 |
CN¥61.59 |
49.4% |
|
RACCOON HOLDINGS (TSE:3031) |
¥965.00 |
¥1893.98 |
49% |
|
TechnoPro Holdings (TSE:6028) |
¥3301.00 |
¥6597.88 |
50% |
|
S Foods (TSE:2292) |
¥2544.00 |
¥5084.09 |
50% |
|
Com2uS (KOSDAQ:A078340) |
₩45950.00 |
₩91675.96 |
49.9% |
|
Siam Wellness Group (SET:SPA) |
THB4.58 |
THB9.12 |
49.8% |
|
Akeso (SEHK:9926) |
HK$74.60 |
HK$147.04 |
49.3% |
Let’s review some notable picks from our screened stocks.
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea with a market cap of approximately ₩3.51 trillion.
Operations: PharmaResearch Co., Ltd.’s revenue segments are not detailed in the provided text.
Estimated Discount To Fair Value: 15.4%
PharmaResearch is trading at ₩337,500, below its estimated fair value of ₩398,985.63. With forecasted revenue growth of 20.4% per year outpacing the Korean market’s 8.1%, and earnings expected to grow significantly at 26.8% annually, the stock appears undervalued based on cash flows despite not being highly undervalued by a significant margin. Recent dividend increases further reflect confidence in its financial health and future prospects.
Overview: Seres Group Co., Ltd. is engaged in the research, development, manufacturing, sale, and supply of automobiles and auto parts in China with a market capitalization of CN¥191.38 billion.
Operations: The company’s revenue from the automobile industry amounts to CN¥125.79 billion.
Estimated Discount To Fair Value: 17.6%
Seres Group Ltd. is trading at CN¥127.08, below its estimated fair value of CN¥154.2, indicating it is undervalued based on cash flows though not by a significant margin. The company’s earnings are forecast to grow significantly at 33.6% annually, outpacing the Chinese market average of 25%. With revenue growth expected at 16.2% per year and a high forecasted return on equity of 33.7%, Seres demonstrates strong financial potential despite recent profitability challenges.
